Nicknam Amir, Khojasteh Pour Sahar, Hashemnejad Mohammad Amin, Hussen Bashdar Mahmud, Safarzadeh Arash, Eslami Solat, Taheri Mohammad, Ghafouri-Fard Soudeh, Jamali Elena
Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran.
Pathol Res Pract. 2023 Apr;244:154429. doi: 10.1016/j.prp.2023.154429. Epub 2023 Mar 27.
The Rho GTPases have prominent roles in cell cycle transition and cell migration. Some members of this family have been found to be mutated in cancers. Moreover, alterations in expression levels and/or activity of these proteins have been reported in many types of cancers. Thus, Rho GTPases are involved in the carcinogenesis. Rho GTPases regulate growth, motility, invasiveness and metastatic ability of breast cancer cells. Long non-coding RNAs (lncRNAs) have been revealed to exert significant effect in the regulation of these proteins via direct routes or through sequestering microRNAs that inhibit Rho GTPases. We aimed to assess expression levels of four Rho GTPase-related lncRNAs, namely NORAD, RAD51-AS1, NRAV and DANCR in breast cancer samples versus non-cancerous specimens from the same individuals. Expression levels of NORAD were shown to be elevated in tumoral tissues compared with non-tumoral tissues (Expression ratio (95% CI)= 5.85 (3.16-10.83), Standard error of mean (SEM)= 0.44, P value< 0.0001). NRAV expression was also higher in tumoral tissues compared with control tissues (Expression ratio=2.85 (1.52-5.35), SEM= 0.45, P value= 0.0013). Similar to these lncRNAs, RHOA was demonstrated to be up-regulated in malignant tissues (Expression ratio=6.58 (3.17-13.63), SEM= 0.52, P value< 0.0001). Although expression ratio values showed up-regulation of RAD51-AS1 and DANCR in cancerous tissues (Expression ratio (95% CI)= 2.2 (1.05-4.6) and 1.35 (0.72-2.53), respectively), P values did not reach significance level (P values=0.0706 and 0.3746, respectively). There were significant associations between expression level of NRAV gene in tumor tissues and a number of parameters including age, histological tumor grade and tubule formation. Taken together, the current study shows dysregulation of a number of RHOA-related lncRNAs in breast cancer in association with abnormal up-regulation of this member of Rho GTPase family and suggests conduction of additional functional studies to unravel their mode of participation in the breast carcinogenesis.
Rho GTP酶在细胞周期转换和细胞迁移中发挥着重要作用。已发现该家族的一些成员在癌症中发生突变。此外,在许多类型的癌症中都报道了这些蛋白质的表达水平和/或活性的改变。因此,Rho GTP酶参与了肿瘤发生。Rho GTP酶调节乳腺癌细胞的生长、运动性、侵袭性和转移能力。长链非编码RNA(lncRNA)已被证明通过直接途径或通过隔离抑制Rho GTP酶的微小RNA,在这些蛋白质的调节中发挥重要作用。我们旨在评估四种与Rho GTP酶相关的lncRNA,即NORAD、RAD51-AS1、NRAV和DANCR在乳腺癌样本与来自同一患者的非癌组织中的表达水平。与非肿瘤组织相比,NORAD在肿瘤组织中的表达水平升高(表达比(95%置信区间)=5.85(3.16-10.83),平均标准误差(SEM)=0.44,P值<0.0001)。与对照组织相比,NRAV在肿瘤组织中的表达也更高(表达比=2.85(1.52-5.35),SEM=0.45,P值=0.0013)。与这些lncRNA类似,RHOA在恶性组织中被证明上调(表达比=6.58(3.17-13.63),SEM=0.52,P值<0.0001)。虽然癌组织中RAD51-AS1和DANCR的表达比值显示上调(表达比(95%置信区间)分别为2.2(1.05-4.6)和1.35(0.72-2.53)),但P值未达到显著水平(P值分别为0.0706和0.3746)。肿瘤组织中NRAV基因的表达水平与包括年龄、组织学肿瘤分级和小管形成在内的一些参数之间存在显著关联。综上所述,本研究表明乳腺癌中一些与RHOA相关的lncRNA失调,与Rho GTP酶家族的这一成员异常上调有关,并建议进行更多功能研究以阐明它们参与乳腺癌发生的模式。